GSK (LON:GSK) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

GSK plc (LON:GSK - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,407.39 ($19.16) and traded as high as GBX 1,528.50 ($20.81). GSK shares last traded at GBX 1,527.73 ($20.80), with a volume of 15,815,270 shares changing hands.

Analyst Upgrades and Downgrades

GSK has been the subject of several recent analyst reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research note on Friday, March 28th. Shore Capital restated a "buy" rating on shares of GSK in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average target price of GBX 1,862.50 ($25.36).

GSK Stock Performance

The company's fifty day moving average price is GBX 1,404.16 and its two-hundred day moving average price is GBX 1,407.39. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The firm has a market capitalization of £62.73 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Insider Buying and Selling

In other GSK news, insider Wendy Becker acquired 536 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was bought at an average cost of GBX 1,515 ($20.63) per share, for a total transaction of £8,120.40 ($11,055.68). Also, insider Emma Walmsley sold 5,473 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.73), for a total transaction of £79,303.77 ($107,969.73). Corporate insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.